Related Experiment Video
Updated: May 26, 2026
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
New insights into molecular mechanisms of sunitinib-associated side effects
Guadalupe Aparicio-Gallego1, Moisés Blanco, Angélica Figueroa
1Clinical Oncology Department and Biomedical Research Institute (INIBIC), A Coruña University Hospital, A Coruña, Spain.
Abstract:
The introduction of targeted therapy represents a major advance in the treatment of tumor progression. Targeted agents are a novel therapeutic approach developed to disrupt different cellular signaling pathways. The tyrosine kinase inhibitor sunitinib specifically blocks multiple tyrosine kinase receptors that are involved in the progression of many tumors. Sunitinib is the current standard of care in first-line treatment of advanced renal cell carcinoma, and it is approved in imatinib-intolerant and imatinib-refractory gastrointestinal stromal tumors. However, it is increasingly evident that sunitinib may display collateral effects on other proteins beyond its main target receptors, eliciting undesirable and unexpected adverse events. A better understanding of the molecular mechanisms underlying these undesirable sunitinib-associated side effects will help physicians to maximize efficacy of sunitinib and minimize adverse events. Here, we focus on new insights into molecular mechanisms that may mediate sunitinib-associated adverse events.
Insights
Sunitinib, a targeted cancer therapy, effectively treats advanced kidney cancer and certain gastrointestinal tumors. However, it can cause unexpected side effects by affecting unintended proteins, necessitating a deeper understanding of these mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted therapy, including tyrosine kinase inhibitors like sunitinib, has advanced cancer treatment by disrupting cellular signaling pathways.
- Sunitinib is a standard treatment for advanced renal cell carcinoma and approved for specific gastrointestinal stromal tumors.
- Off-target effects of sunitinib can lead to unexpected adverse events, impacting patient outcomes.
Purpose of the Study:
- To explore the molecular mechanisms behind sunitinib-associated adverse events.
- To provide insights that can help optimize sunitinib efficacy and minimize side effects.
Main Methods:
- Review of current literature on sunitinib's molecular targets and off-target interactions.
- Analysis of signaling pathways affected by sunitinib beyond its primary targets.
Main Results:
- Sunitinib's inhibition of multiple tyrosine kinase receptors is crucial for its therapeutic effect.
- Evidence suggests sunitinib interacts with additional proteins, contributing to its adverse event profile.
- Understanding these off-target interactions is key to managing side effects.
Conclusions:
- Further research into the molecular basis of sunitinib's side effects is essential.
- Improved understanding will aid clinicians in maximizing sunitinib's benefits while mitigating risks.
- This knowledge can lead to safer and more effective cancer treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...